Several ribosomal proteins including L11 have been shown to activate p53 by inhibiting oncoprotein MDM2, leading to inhibition of cell cycle progression. Our recent study showed that L11 also inhibits oncoprotein c-Myc. Overexpression of L11 inhibits c-Myc-induced transcription and cell proliferation, while reduction of endogenous L11 increases these c-Myc activities. Interestingly, L11 is a transcriptional target of c-Myc, thus forming a negative feedback loop. We further showed that L11 competes with co-activator TRRAP for binding to c-Myc through the Myc box II (MB II) and reduces histone H4 acetylation at c-Myc target gene promoters. In addition, L11 appears to regulate c-Myc levels. Knocking down L11 markedly increases the mRNA and protein levels of endogenous c-Myc. These results suggest that L11 also inhibits cell cycle progression by regulating the c-Myc pathway. Here we further discuss the implications of this regulation and questions that this finding raises.
INTRODUCTION
Ribosomal biogenesis, a complex process for making the ribosome, is of fundamental importance for normal cell growth and proliferation. Interfering with the production of ribosomes severely retards cell growth and animal development. For example, deletion of ribosomal protein L16 in yeast results in a lethal phenotype due to deficiency of the 60 S subunit of the ribosome. 1 A class of dominant mutants called minutes in drosophila harbor mutations in genes encoding ribosomal proteins. These minutes display similar phenotypes that are characterized by delayed larval development, short thin bristles, recessive lethality, as well as some variable phenotypes including small body size, female sterility, and malformation of wings and eyes resulting from reduced number of ribosomes and protein synthesis. 2,3 In mammals, naturally occurring mutations are found in genes encoding ribosomal proteins S19 and L24. Specifically, heterozygous null mutations in the human S19 gene are present in about 25% of patients with Diamond-Blackfan anemia (DBA), a syndrome characterized by anemia and an increased susceptibility to hematopoietic malignancies. 4 Additionally, a spontaneously occurring semindominant and homozygous lethal mutant called Belly spot and tail (Bst) in mice was found to harbor a short deletion mutation of the L24 gene. 5 Complete loss of S19 or L24 is embryonically lethal, reinforcing the profound effect of ribosomal biogenesis on cell growth and development. 5, 6 In addition, genetically manipulated inactivation of individual ribosomal proteins L22, L29, and S6 has recently been reported in mice. Conditional homozygous deletion of the S6 gene in mouse liver resulted in the failure of liver cell proliferation following partial hepatectomy. 7 Heterozygous deletion of S6 led to p53-dependent cell cycle arrest in somatic T lymphocytes 8 and in embryos during gastrulation. 9 These studies suggest that S6-haploinsufficiency triggers the activation of a p53-dependent cell cycle checkpoint. 10 In contrast, L29 null mice are viable but display low birth weight, reduced postnatal viability, and a global skeleton growth defect. L29 null MEFs display decreased cell proliferation and protein synthesis. 11 L22 null mice are also viable and develop normally, but harbor a selective defect in the development of αβT lymphocytes due to activation of a p53-dependent checkpoint, 12 suggesting that certain ribosomal proteins may perform cell-type specific or stage-specific functions. Altogether, genetic studies firmly support that ribosomal biogenesis is essential for cell growth and proliferation as well as animal development.
On the other hand, aberrant over-production of ribosomes and increased translational activity contribute to cell transformation and tumorigenesis. 13 For example, overexpression of the ribosomal protein S3a induces transformation of NIH 3T3 cells and tumor formation in nude mice by inhibiting apoptosis. 14 Individual overexpression of human translation initiation factor eIF3 subunits and eIF-4E enhances cell proliferation and induces cellular transformation. 15-17 Other individual ribosomal proteins, such as S8, L12, L23a, L27 and L30, were upregulated in various tumors. 18,19 Although it is still not clear how the overexpression of individual ribosomal proteins contributes to tumorigenesis and whether increased translation on its own can contribute to tumorigenesis, the above studies point to a clear role for deregulation of ribosomal biogenesis in tumorigeneis. Thus, ribosomal biogenesis must be under tight control in order to constantly coordinate with cell growth and proliferation.
REGULATION OF RIBOSOMAL BIOGENESIS BY TUMOR SUPPRESSORS AND ONCOGENES
Consistent with the need to coordinate ribosomal biogenesis with cell growth and proliferation, the tumor suppressor proteins p53, RB, ARF, and PTEN have all been shown to inhibit ribosomal biogenesis (Fig. 1) . Specifically, p53, RB, and RB family member p130 prevent the promoter recruitment of TFIIIB, a RNA Polymerase III (Pol III)-specific transcription factor, leading to repression of Pol III-mediated transcription of tRNA and 5S rRNA required for ribosome function and assembly. 20-28 Transcription of rDNA to generate the rRNA components of the ribosome is dependent on basal Pol I-specific transcription factors UBF and TBP-containing SL1/TIF-IB complex. Both p53 and RB interfere with the assembly of the UBF-SL1-Pol I initiation complex on the rDNA promoter, leading to repression of Pol Imediated transcription of rRNAs. 29-32 PTEN also represses Pol I-mediated transcription of rRNA by disrupting the SL1/TIF-IB complex and reducing the occupancy of the SL1 subunits on the rDNA gene promoter. 33 Finally, ARF has been shown to inhibit rRNA processing possibly through enhancing proteasome-mediated degradation of nucleophosmin (also called B23), an important nucleolar endoribonuclease required for rRNA processing. 34, 35 In addition, ARF specifically interacts with the rDNA gene promoter and may play a direct function in rRNA transcription. 36 ARF also suppresses Pol III-mediated tRNA synthesis independently of p53. 37 In parallel, ARF activates p53 by blocking its negative regulator MDM2, perhaps enhancing the suppression of the synthesis of rRNAs imposed by p53. In summary, all of the above tumor suppressors efficiently suppress ribosomal biogenesis presumably to coordinate with their negative regulation of the cell cycle.
On the other hand, the tumor-promoting activity of the c-Myc oncoprotein is associated with its role in enhancing ribosomal biogenesis (Fig. 1) . c-Myc has been shown to regulate transcription by all three RNA polymerases. 38,39 Specifically, c-Myc enhances Pol Icatalyzed rRNA synthesis by binding to TBP and TBP-associated factors (TAFs), thereby facilitating the recruitment of Pol I to the rDNA promoter. 40-42 c-Myc also enhances Pol IIImediated 5S and tRNA transcription by directly interacting with and activating TFIIIB. 43 In addition, Pol II-mediated transcription of genes encoding ribosomal proteins, ribosome assembly proteins, and translation initiation and elongation factors is stimulated by c-Myc. 44-47 These studies imply that many critical tumor suppressors and oncoproteins exert their function by regulating the dynamics of ribosome biogenesis.
REGULATION OF THE P53-MDM2 FEEDBACK LOOP BY RIBOSOMAL PROTEINS
Nature has evolved many elegant feedback surveillance mechanisms for important cellular processes. Thus an interesting question arises as to whether ribosomal biogenesis components, such as individual ribosomal proteins, in turn regulate the activity of tumor suppressors and oncogenes. This question has recently been investigated by a number of groups, including our own. It is now clear that several ribosomal proteins, including L5, L11, L23, S7, and L26, can regulate p53 activity in response to different stresses by distinct mechanisms. [48] [49] [50] [51] [52] [53] [54] [55] We found that ribosomal proteins L5, L11, and L23 appear to be the major steady-state components of an MDM2-associated protein complex. 49,51 These L proteins as well as S7, a small subunit component, were shown to bind to MDM2 and inhibit MDM2-mediated p53 ubiquitination and degradation, leading to p53 activation. [48] [49] [50] [51] [52] [53] 55 These ribosomal proteins play a crucial role in p53 responses to perturbation of ribosomal biogenesis (ribosomal stress, also called nucleolar stress), such as those induced by the treatment with actinomycin D or 5-FU, 51,56, 57 serum starvation, 58 or genetic disruption of the transcription initiation factor TIF-IA. 59
Based upon these studies, it is predicted that expression of dominant negative mutant Bop1, 60 or genetic disruption of ribosomal protein S6 8 may also activate p53 by utilizing these ribosomal proteins. Furthermore, L26 has been shown to enhance p53 translation in response to DNA damage. 54 Thus, while p53 inhibits ribosome biogenesis, a group of individual ribosomal proteins, in turn, activates p53, ensuring that ribosome homeostasis is preserved. Since c-Myc is closely linked to ribosome biogenesis, we asked the question of whether individual ribosomal proteins also regulate c-Myc activity. Indeed, our recent study has demonstrated that L11 inhibits c-Myc activity through a negative feedback mechanism. 61
FEEDBACK INHIBITION OF c-Myc ACTIVITY BY L11
The c-Myc oncoprotein is a basic helix-loop-helix leucine-zipper (bHLH/LZ) transcriptional factor. It forms a heterodimer with its partner protein Max and binds to cognate DNA sequence elements called E-box (CACGTG). 39 The conserved Myc box (MB) II in the N-terminal transcriptional activation domain (TAD) recruits several critical co-activators for c-Mycmediated transcription, including TRRAP, a core component of the TIP60 and GCN5 containing histone acetyltransferase (HAT) complexes, 62 TIP48/TIP49 ATPases, components of chromatin remodeling complexes, 63 and Skp2, a component of the SCF skp2 E3 ligase complex. 64, 65 In addition, the C-terminus of c-Myc recruits co-activators p300/CBP histone acetyltransferase. 39,66 By acetlyating histones and remodeling chromatin structure to a transcriptionally active state, these co-activators mediate c-Myc-driven transcription of its target genes that are implicated in cell growth, proliferation, differentiation, apoptosis, metabolism, and neoplastic transformation. 39,67,68 Although c-Myc is essential for normal cell growth and animal development, 69 deregulated expression of c-Myc due to chromosomal translocations, gene amplification or viral insertions at the c-myc locus is linked to many types of human cancers. 39,70 Constitutive or inducible expression of a c-myc transgene leads to neoplastic pre-malignant and malignant phenotypes in mice. 70-72 Thus, precise regulation of c-Myc expression and transcriptional activity is critical for normal cellular function. Consistent with this notion, c-Myc expression is regulated at multiple levels, including transcription, mRNA stability, translation, and post-translation protein stability. 73, 74 In order to test whether individual ribosomal proteins could regulate c-Myc activity, we first employed transfection-luciferase assays. We found that overexpression of L11 significantly Interestingly, the inhibitory effect of L11 on c-Myc activity resembles the regulation of c-Myc by ARF. 76-78 Similarly, ARF binds to the MB II 79 and suppresses c-Myc activity, although it has not been tested if ARF may do so by interfering with the TRRAP recruitment and subsequent histone acetylation. Intriguingly, the inhibitory effect of ARF on c-Myc is selective to its transactivational, but not repression, activity. 78 It is still unclear whether this selectivity would also be true to L11. Also, it is unknown whether L11 and/or ARF could interfere with the recruitment of other co-factors, such as TIP48/TIP49 or Skp2, by c-Myc to c-Myc target promoters. These are certainly interesting and important questions for future investigation.
L11 REGULATES c-Myc LEVELS
In addition to directly inhibiting c-Myc-dependent transcription by competing with TRRAP for promoter binding, we have also shown that L11 expression is well correlated with the change in c-Myc levels. 61 Initially, we found that reduction of L11 by siRNA drastically induced the protein level of c-Myc in human osteosarcoma U2OS cells. This protein induction was at least partly due to increased levels of c-myc mRNA (Fig. 2) . The increase in c-myc mRNA might be caused by an increase in either gene transcription or mRNA stability. It has been shown that c-Myc can auto-inhibit its own transcription, though by an unknown mechanism. 80,81 It is possible that knockdown of L11 may derepress this autoregulatory inhibition imposed by c-Myc itself. Toward this end, it would be worth investigating whether L11 associates with c-Myc at the promoter region of the c-myc gene. Another possibility is that L11 may regulate c-myc gene transcription independently of its binding to the c-Myc protein. For example, L11 might directly interfere with transcriptional machineries or with the remodeling of chromatin structure in the promoter region of the c-myc gene by binding to histones, since several drosophila ribosomal proteins have recently been shown to associate with linker histone H1 and suppress transcription of a set of genes. 9 Correlated with this possibility, we have recently purified an L11-associated complex that also contains the linker histone H1 (data not shown).
L11 could also influence c-myc mRNA stability. c-myc mRNA has a short half-life of 15-30 minutes. Two cis-acting sequence elements have been shown to regulate c-myc mRNA turnover: an AU-rich element (ARE) in the 3′-untranslated region (3′-UTR) and a ~250 nucleotide region called coding region instability determinant (CRD). Several ARE binding proteins, including AUF1 82 and HuR, 83 have been found to bind to the c-myc ARE and act as c-myc mRNA destabilizing factors. Furthermore, CRD-binding protein (CRD-BP) binds to the CRD in the c-myc mRNA and protects it from endoribonuclease cleavage within the CRD, leading to stabilization of c-myc mRNA. 84-86 The latter regulation has been implicated in the stabilization of c-myc mRNA in response to β-catenin signaling. 87 Thus, one interesting and pertinent question for future study would be if L11 regulates c-myc mRNA levels through interaction with these components.
Since knockdown of L11 leads to an increase in c-Myc mRNA and protein expression, one would predict that overexpression of L11 might reduce c-Myc levels. However, we surprisingly observed an increase in the total level of ectopically expressed c-Myc when L11 was overexpressed. This increase was accompanied by a concurrent decrease in the population of NP-40-extractable and soluble c-Myc. One possible explanation is that L11 might facilitate the subcellular localization of c-Myc to insoluble chromatin-bound material or to nucleolar compartments, resulting in the decrease of soluble c-Myc. This indeed was the case, as overexpression of L11 relocalized a fraction of ectopic c-Myc into the nucleolus (Fig. 3) . This sequestration required the interaction of c-Myc with L11, as a c-Myc-binding defective mutant of L11 did not re-localize c-Myc into the nucleolus (data not shown). c-Myc was shown to be degraded in the nucleolus by the proteasome, 88 however its level was elevated in this subcellular compartment in the presence of overexpressed L11 (Fig. 3) , suggesting that L11 may simply block c-Myc degradation in the nucleolus. Also, in our preliminary study using chromatin immunoprecipitation (ChIP) assays, we found that overexpression of L11 increased the residence of c-Myc at its target gene promoters (data not shown), suggesting that L11 may block c-Myc turnover at the promoter as well. Others have shown that Skp2-mediated c-Myc turnover at the promoter is essential for proper c-Myc function and Spk2 also binds to the MB II. 64,65 Hence, it is tempting to speculate that L11 may compete with Skp2 for binding to cMyc at its target gene promoters, leading to accumulation of inactive c-Myc at these promoters.
Taken together, the evidence as described here suggests that multiple mechanisms may account for the inhibitory effect of L11 on c-Myc activity: directly blocking the transactivational activity of c-Myc at c-Myc target gene promoters, controlling c-myc mRNA levels, and sequestering excess c-Myc protein. However, further studies are necessary to verify and dissect the latter two mechanisms. This complex regulation also highlights the important role for L11 in regulating c-Myc and may be a key feedback regulation during ribosomal biogenesis.
IS THE INHIBITION OF c-Myc SPECIFIC TO L11?
In addition to L11, there are other ribosomal proteins that have been shown to play a role in regulating p53 activities. 48-55 Thus, an obvious question is whether the effect of L11 on cMyc is specific to this ribosomal protein. In our recently reported work, 61 we have attempted to address this question by testing several other ribosomal proteins for their binding capacity to c-Myc. We found that L29, L30, and S12 do not bind to c-Myc. In addition, neither overexpression of L29 nor knockdown of L29 affected c-Myc activity. 61 Thus clearly, the inhibition of c-Myc activity is not a general effect for all ribosomal proteins. However, L11 is not the only ribosomal protein that binds to c-Myc either. Among our tested ribosomal proteins, L5, L23, and S7, which have all been shown to bind to MDM2, 48,49,51, 52 were found to bind to c-Myc as well, though with different binding affinity (data not shown).
Although further studies are necessary to clarify whether these ribosomal proteins act similarly to L11, these results suggest that a group of individual ribosomal proteins may target both cMyc and the MDM2-p53 pathways. In support of this hypothesis, our preliminary work shows that L29, L30, and S12, which do not bind to c-Myc, also do not bind to MDM2 (data not shown). The use of a common subset of ribosomal proteins to control both MDM2 and c-Myc activity may ensure the coordination of ribosomal biogenesis with cell cycle progress. It is also possible that these ribosomal proteins may work in concert or synergistically to reach an optimal and efficient effect on c-Myc activity. Or, they may work independently in response to different ribosomal biogenesis stresses. More experiments are necessary to define the individual role for each of these ribosomal proteins in regulating both c-Myc activity and cmyc mRNA levels.
BIOLOGY OF THE L11-C-MYC FEEDBACK LOOP
Our finding that L11 regulates c-Myc level and activity raises additional questions: what is the physiological significance of the L11-c-Myc inhibitory feedback regulation? Under what circumstance is this feedback loop activated? Is it responsive to ribosomal stress signals? Presumably, the excess molecules of L11 that can target c-Myc may be generated from either a net increase in L11 synthesis or release of L11 from the intact ribosome into ribosome-free pools. Deregulated and high levels of c-Myc apparently enhance ribosomal biogenesis and L11 production. Our finding suggests that this increased L11 could then target c-Myc and turn it off. A future project would be to confirm this feedback loop in vivo by employing genetically manipulated mouse models.
The balance of ribosome-bound and ribosome-free L11 molecules may serve as an important signal for activation of the L11-c-Myc feedback loop. Under nucleolar stress, L11 may be released from the nucleolus as the result of the stalled process of ribosomal biogenesis. In such a case, ribosome-free L11 may be in excess and then execute the inhibitory effect on c-Myc activity, as it does to the MDM2-p53 pathway. 58 Our study also indicates that L11 regulates c-Myc activity dependent on growth signals. 61 In response to serum starvation, the association of L11 with c-Myc target gene promoters increased and thus L11 competed with TRRAP for binding to these promoters, leading to inhibition of c-Myc-dependent transcription. By doing so, L11 may play a role in maintaining a silent or inhibited status of ribosomal biogenesis when growth conditions are unfavorable for cell growth or proliferation. Conversely, In response to serum re-stimulation, c-Myc levels rapidly increased while L11 binding to c-Myc target gene promoters inversely decreased, indicating that the L11 repression of c-Myc activity is derepressed at a stage when c-Myc activity is required for cells to proliferate. 61 It seems that the acutely increased L11 molecules in the early serum re-stimulation stage do not target c-Myc instantly. Instead, these L11 molecules might be used to limit c-Myc activity at the later stage of serum stimulation in order to prevent aberrant cell growth. The increased L11 could just be simply incorporated into ribosomes for protein synthesis. 
CONCLUSION
Recent studies including ours as described here have demonstrated an important role for L11 in cell cycle control by regulating the MDM2-p53 feedback loop as well as the c-Myc pathway. 53, 55, 58, 73 Remarkably, L11 resembles ARF in these regulations, but also works independently of ARF. In light of currently available evidence, we propose a model (Fig. 4) for the action of L11 and ARF. In this model, L11 may primarily acts as a sensor of aberrant ribosomal biogenesis, whereas ARF primarily acts as a sensor of oncogenic stress. 35 The remaining questions would be: whether these two stress signaling pathways crosstalk with each other, whether L11 itself possesses tumor suppressor function, and whether L11-c-Myc and L11-MDM2 interactions have implications in tumor treatment? L11 regulates c-myc mRNA levels. U2OS cells were transfected with scrambled or L11 siRNAs against two different sequences followed by semi-quantitative RT-PCR assays. A schematic model illustrating the dual effects of L11 and ARF on cell cycle arrest. L11, in response to nucleolar stress, and, ARF in response to oncogenic stress, bind to MDM2 and suppress MDM2-mediated p53 inhibition, leading to p53 activation. They also bind to c-Myc and inhibit its transactivation activity. Bars indicate inhibition, whereas arrows denote activation.
